These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26925786)

  • 61. JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity.
    Xun J; Wang D; Shen L; Gong J; Gao R; Du L; Chang A; Song X; Xiang R; Tan X
    Oncotarget; 2017 Mar; 8(13):21918-21929. PubMed ID: 28423536
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Correlation of ALDH1, CD44, OCT4 and SOX2 in tongue squamous cell carcinoma and their association with disease progression and prognosis.
    Huang CF; Xu XR; Wu TF; Sun ZJ; Zhang WF
    J Oral Pathol Med; 2014 Aug; 43(7):492-8. PubMed ID: 24450601
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gradual DNA demethylation of the Oct4 promoter in cloned mouse embryos.
    Yamazaki Y; Fujita TC; Low EW; Alarcón VB; Yanagimachi R; Marikawa Y
    Mol Reprod Dev; 2006 Feb; 73(2):180-8. PubMed ID: 16245355
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
    Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
    Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The correlation between promoter methylation status and the expression level of O6-methylguanine-DNA methyltransferase in recurrent glioma.
    Suzuki T; Nakada M; Yoshida Y; Nambu E; Furuyama N; Kita D; Hayashi Y; Hayashi Y; Hamada J
    Jpn J Clin Oncol; 2011 Feb; 41(2):190-6. PubMed ID: 21148162
    [TBL] [Abstract][Full Text] [Related]  

  • 66. DNA methylation level of promoter region of activating transcription factor 5 in glioma.
    Hua XM; Wang J; Qian DM; Song JY; Chen H; Zhu XL; Zhou R; Zhao YD; Zhou XZ; Li L; Zhang L; Song XX; Wang B
    J Zhejiang Univ Sci B; 2015 Sep; 16(9):757-62. PubMed ID: 26365117
    [TBL] [Abstract][Full Text] [Related]  

  • 67. ISG15 enhances glioma cell stemness by promoting Oct4 protein stability.
    Dai Y; Yu T; Yu C; Lu T; Zhou L; Cheng C; Ni H
    Environ Toxicol; 2022 Sep; 37(9):2133-2142. PubMed ID: 35506701
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In silico identification of natural product inhibitors against Octamer-binding transcription factor 4 (Oct4) to impede the mechanism of glioma stem cells.
    Nayak C; Singh SK
    PLoS One; 2021; 16(10):e0255803. PubMed ID: 34613998
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Messenger RNA fingerprinting analysis using arbitrarily primed PCR (RAP) of genes expressed during rat C6 glioma cell differentiation.
    Sakai H; Nakashima S; Nakatani K; Yoshimura S; Nishimura Y; Sakai N; Nozawa Y
    Brain Tumor Pathol; 1997; 14(2):119-23. PubMed ID: 15726790
    [TBL] [Abstract][Full Text] [Related]  

  • 70. DNA Damage Signaling-Induced Cancer Cell Reprogramming as a Driver of Tumor Relapse.
    Filipponi D; Emelyanov A; Muller J; Molina C; Nichols J; Bulavin DV
    Mol Cell; 2019 May; 74(4):651-663.e8. PubMed ID: 30954402
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Cytophotometric investigations in recurrent gliomas: correlation of DNA-parameters with WHO-grade, proliferation index and recurrence-free interval].
    Schneider W; Kellermann S; Nenning H; Thal DR; Schober R
    Pathologe; 1999 Nov; 20(6):321-9. PubMed ID: 10591949
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Progenitor cells and glioma formation.
    Holland EC
    Curr Opin Neurol; 2001 Dec; 14(6):683-8. PubMed ID: 11723374
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Methylation profile of bovine
    Zhou XY; Liu LL; Jia WC; Pan CY
    J Integr Agric; 2016 Mar; 15(3):618-628. PubMed ID: 32288951
    [TBL] [Abstract][Full Text] [Related]  

  • 74. OCT4 mutations in human erythroleukemic cells: implications for multiple drug resistance (MDR) phenotype.
    Oliveira BR; Figueiredo MA; Trindade GS; Marins LF
    Mol Cell Biochem; 2015 Feb; 400(1-2):41-50. PubMed ID: 25355160
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Methionine regulates self-renewal, pluripotency, and cell death of GIC through cholesterol-rRNA axis.
    Yokogami K; Kikuchi T; Watanabe T; Nakatake Y; Yamashita S; Mizuguchi A; Takeshima H
    BMC Cancer; 2022 Dec; 22(1):1351. PubMed ID: 36564758
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cloning and Characterization of 3.1kb Promoter Region of the Oct4 Gene from the Fischer 344 Rat.
    He H; McHaney M; Hong J; Weiss ML
    Open Stem Cell J; 2009 Jan; 1(1):30-39. PubMed ID: 22347989
    [TBL] [Abstract][Full Text] [Related]  

  • 77. DNA repair in normal and cancer stem cells, with special reference to the central nervous system.
    Frosina G
    Curr Med Chem; 2009; 16(7):854-66. PubMed ID: 19275598
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Integrating real-time in vivo tumour genomes for longitudinal analysis and management of glioma recurrence.
    Sheng Z; Yu J; Deng K; Bu Y; Wu S; Xu S; Gao Y; Zhang Q; Yan Z; Bu C; Chen Z; Gu J; Jia Y; Gao X; Zemmar A; Sumardi F; Hernesniemi J; Kong L; Liu G; Li M; Wang M; Li T; Bu X
    Clin Transl Med; 2021 Nov; 11(11):e567. PubMed ID: 34841677
    [No Abstract]   [Full Text] [Related]  

  • 79. Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
    Riva G; Butta V; Cilibrasi C; Baronchelli S; Redaelli S; Dalprà L; Lavitrano M; Bentivegna A
    Oncol Rep; 2016 May; 35(5):2811-24. PubMed ID: 26986767
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
    Parker NR; Hudson AL; Khong P; Parkinson JF; Dwight T; Ikin RJ; Zhu Y; Cheng ZJ; Vafaee F; Chen J; Wheeler HR; Howell VM
    Sci Rep; 2016 Mar; 6():22477. PubMed ID: 26940435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.